Krystal Biotech, Inc. (NASDAQ:KRYS) Sees Significant Decline in Short Interest

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) was the recipient of a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 3,370,000 shares, a decline of 8.9% from the December 15th total of 3,700,000 shares. Based on an average daily trading volume, of 247,300 shares, the short-interest ratio is currently 13.6 days.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total value of $4,119,500.00. Following the completion of the transaction, the insider now owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 14.10% of the company's stock.

Institutional Investors Weigh In On Krystal Biotech

Hedge funds have recently made changes to their positions in the company. Segall Bryant & Hamill LLC increased its stake in shares of Krystal Biotech by 352.4% during the third quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company's stock valued at $28,605,000 after buying an additional 122,407 shares during the period. State Street Corp increased its position in Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company's stock valued at $264,455,000 after purchasing an additional 119,936 shares during the period. Franklin Resources Inc. raised its holdings in shares of Krystal Biotech by 34.2% in the 3rd quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock valued at $43,774,000 after purchasing an additional 62,178 shares in the last quarter. Braidwell LP raised its stake in Krystal Biotech by 57.4% in the third quarter. Braidwell LP now owns 168,691 shares of the company's stock worth $30,707,000 after buying an additional 61,512 shares in the last quarter. Finally, Public Sector Pension Investment Board purchased a new stake in shares of Krystal Biotech during the 2nd quarter worth $10,037,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on KRYS shares. Chardan Capital reaffirmed a "buy" rating and set a $212.00 price objective on shares of Krystal Biotech in a research note on Wednesday, December 18th. HC Wainwright reaffirmed a "buy" rating and set a $221.00 price target on shares of Krystal Biotech in a research note on Wednesday, December 18th. Finally, Citigroup upped their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $206.67.

Krystal Biotech Trading Up 2.5 %

Shares of NASDAQ KRYS traded up $3.58 during mid-day trading on Friday, reaching $148.39. The company had a trading volume of 180,087 shares, compared to its average volume of 248,304. The stock has a market cap of $4.27 billion, a price-to-earnings ratio of 83.84 and a beta of 0.85. Krystal Biotech has a 52 week low of $107.50 and a 52 week high of $219.34. The business's 50-day moving average is $170.98 and its 200-day moving average is $182.15.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.84 by $0.07. The business had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company's revenue for the quarter was up 879.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.67) EPS. As a group, equities research analysts forecast that Krystal Biotech will post 3.03 earnings per share for the current year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).